Skip to content

A retrospective analysis of the diagnosis, staging and prognosis prediction of esophageal cancer based on 18F-FDG PET/CT combined with artificial intelligence,radiogenomics and clinical characteristics

A retrospective analysis of the diagnosis, staging and prognosis prediction of esophageal cancer based on 18F-FDG PET/CT combined with artificial intelligence,radiogenomics and clinical characteristics

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400093068
Enrollment
Unknown
Registered
2024-11-28
Start date
2024-11-30
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal cancer

Interventions

Observation group:None

Sponsors

Drum Tower Hospital Affiliated to Nanjing University Medical School
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Patients with esophageal abnormalities detected by 18F-FDG PET/CT PET/CT; 2.Aged 18 years or older; 3. Image quality meets the diagnostic criteria; 4.Complete clinical medical records, pathology and follow-up data; 5.Reliable follow-up data, with a minimum follow-up time of 1 year, including surgical information, survival status, recurrence information and survival time.

Exclusion criteria

Exclusion criteria: 1. Patients with other malignant tumors; 2. The patient has received anti-tumor therapy in the past; 3. Lack of complete treatment or follow-up data; 4. Have serious comorbidities that affect the prognosis assessment, such as uncontrolled heart disease, liver failure, etc.

Design outcomes

Primary

MeasureTime frame
Parameters related to radiogenomics;

Countries

China

Contacts

Public ContactFan Xin

Drum Tower Hospital Affiliated to Nanjing University Medical School

fanxindora@163.com+86 131 9531 2906

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026